Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office

This article was originally published in The Tan Sheet

Executive Summary

NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26
Advertisement

Related Content

HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR
NCCAM PC-SPES Clinical Research Could Resume With “Clean” Product
HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR
HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR
HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR
Botanical Drug CMC Requirements Should Track OTC Monographs - AHPA
Botanical Drug Product Guidance Sets Foreign Marketing Data Requirements
Botanical Drug Product Guidance Sets Foreign Marketing Data Requirements

Topics

Advertisement
UsernamePublicRestriction

Register

PS094487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel